Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Receives Average Rating of “Hold” from Analysts

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has received an average recommendation of “Hold” from the five analysts that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $45.75.

Several brokerages have issued reports on ETON. Zacks Research lowered Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday. B. Riley Financial upped their target price on Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, March 20th. HC Wainwright raised their price target on Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. Canaccord Genuity Group set a $60.00 price target on Eton Pharmaceuticals in a research note on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Tuesday, April 21st.

Eton Pharmaceuticals Stock Down 3.4%

Shares of NASDAQ:ETON opened at $37.19 on Friday. The firm has a 50 day simple moving average of $33.14 and a 200-day simple moving average of $24.39. Eton Pharmaceuticals has a twelve month low of $13.78 and a twelve month high of $39.48. The company has a current ratio of 1.21, a quick ratio of 0.88 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $1.02 billion, a PE ratio of -531.21 and a beta of 0.86.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Thursday, May 14th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. The company had revenue of $24.27 million during the quarter, compared to analysts’ expectations of $22.31 million. On average, equities analysts predict that Eton Pharmaceuticals will post 0.75 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider David Krempa sold 42,797 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the transaction, the insider directly owned 25,249 shares in the company, valued at approximately $843,064.11. This trade represents a 62.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jennifer Mckie Adams sold 50,000 shares of Eton Pharmaceuticals stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the completion of the transaction, the director directly owned 50,000 shares in the company, valued at $1,624,000. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 150,000 shares of company stock worth $4,853,921. Insiders own 16.49% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quarry LP purchased a new stake in shares of Eton Pharmaceuticals in the third quarter valued at about $37,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Eton Pharmaceuticals during the fourth quarter worth about $44,000. Legal & General Group Plc purchased a new position in shares of Eton Pharmaceuticals during the second quarter worth about $41,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Eton Pharmaceuticals during the fourth quarter worth about $74,000. Finally, SG Americas Securities LLC acquired a new position in Eton Pharmaceuticals in the 4th quarter valued at about $109,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.